clorazepate ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
diazepam derivatives 711 57109-90-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • clorazepate monopotassium
  • clorazepate potassium
  • clorazepic acid
  • clorazepate
  • chlorazepate
  • clorazepate dipotassium
  • dipotassium clorazepate
  • potassium clorazepate
A water-soluble benzodiazepine derivative effective in the treatment of anxiety. It has also muscle relaxant and anticonvulsant actions.
  • Molecular weight: 314.73
  • Formula: C16H11ClN2O3
  • CLOGP: 2.51
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 2
  • TPSA: 78.76
  • ALOGS: -4.10
  • ROTB: 2

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
20 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 5.45 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 91 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.20 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.10 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2.40 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
June 23, 1972 FDA RECORDATI RARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Coma 219.83 17.39 133 8923 56746 50539322
Coma blister 105.11 17.39 19 9037 136 50595932
Suicide attempt 99.90 17.39 79 8977 51653 50544415
Somnolence 81.05 17.39 118 8938 154867 50441201
Seizure 66.36 17.39 93 8963 117781 50478287
Disorientation 65.93 17.39 53 9003 35431 50560637
Toxic epidermal necrolysis 65.66 17.39 43 9013 20949 50575119
Neurological decompensation 62.28 17.39 21 9035 2249 50593819
Erythrodermic psoriasis 57.39 17.39 16 9040 905 50595163
Overdose 56.58 17.39 79 8977 99648 50496420
Drug abuse 55.97 17.39 61 8995 59785 50536283
Tissue infiltration 55.44 17.39 14 9042 539 50595529
Dermatitis exfoliative 55.22 17.39 24 9032 5118 50590950
Basal ganglion degeneration 54.45 17.39 13 9043 395 50595673
Drug interaction 54.35 17.39 114 8942 199507 50396561
Antithrombin III 54.03 17.39 11 9045 156 50595912
Behaviour disorder 53.61 17.39 19 9037 2361 50593707
Fall 51.75 17.39 154 8902 334778 50261290
Rhabdomyolysis 51.60 17.39 48 9008 38979 50557089
Uterine enlargement 46.34 17.39 14 9042 1052 50595016
Stupor 46.05 17.39 19 9037 3564 50592504
Hyperthyroidism 45.71 17.39 28 9028 12147 50583921
Electrolyte imbalance 43.77 17.39 31 9025 17138 50578930
Monoplegia 43.53 17.39 17 9039 2766 50593302
Euphoric mood 40.54 17.39 18 9038 4037 50592031
Anaesthesia 40.52 17.39 10 9046 350 50595718
Inguinal hernia 39.87 17.39 14 9042 1692 50594376
Multiple organ dysfunction syndrome 39.73 17.39 47 9009 50290 50545778
Loss of consciousness 38.69 17.39 68 8988 104285 50491783
Psychogenic seizure 37.02 17.39 13 9043 1572 50594496
Toxicity to various agents 34.93 17.39 100 8956 212399 50383669
Poisoning deliberate 34.40 17.39 20 9036 7892 50588176
Psychomotor hyperactivity 33.92 17.39 21 9035 9280 50586788
Cholecystitis 32.96 17.39 24 9032 13847 50582221
Drug monitoring procedure incorrectly performed 32.61 17.39 7 9049 130 50595938
Sudden cardiac death 30.68 17.39 12 9044 1960 50594108
Intentional overdose 30.30 17.39 46 9010 62458 50533610
Dysaesthesia 29.27 17.39 14 9042 3721 50592347
Drug ineffective 29.12 17.39 65 8991 819268 49776800
Granulomatous liver disease 29.07 17.39 9 9047 734 50595334
Hypochromic anaemia 28.80 17.39 11 9045 1685 50594383
Eosinophilia 28.70 17.39 25 9031 18627 50577441
Klebsiella infection 28.17 17.39 17 9039 7177 50588891
Neuroleptic malignant syndrome 28.14 17.39 20 9036 11110 50584958
Joint swelling 28.12 17.39 5 9051 245281 50350787
Anterograde amnesia 28.01 17.39 8 9048 494 50595574
Respiratory disorder 27.77 17.39 31 9025 31156 50564912
Social avoidant behaviour 26.63 17.39 12 9044 2785 50593283
Derailment 25.90 17.39 5 9051 53 50596015
Serotonin syndrome 24.50 17.39 26 9030 24687 50571381
Intervertebral disc disorder 24.36 17.39 13 9043 4347 50591721
Rash 23.78 17.39 26 9030 437445 50158623
Depressed level of consciousness 23.44 17.39 37 9019 51916 50544152
Lung disorder 23.18 17.39 34 9022 44765 50551303
Livedo reticularis 22.87 17.39 10 9046 2162 50593906
Tremor 22.79 17.39 58 8998 114845 50481223
Somatic delusion 22.75 17.39 7 9049 559 50595509
Hyperpyrexia 22.59 17.39 11 9045 3038 50593030
Conversion disorder 22.34 17.39 9 9047 1587 50594481
Mydriasis 22.15 17.39 17 9039 10610 50585458
Abdominal discomfort 22.07 17.39 7 9049 231634 50364434
Hyperventilation 21.74 17.39 13 9043 5396 50590672
Cutaneous vasculitis 21.58 17.39 12 9044 4350 50591718
Neonatal aspiration 21.03 17.39 5 9051 149 50595919
Cyanosis 20.68 17.39 19 9037 15165 50580903
Abdominal tenderness 20.56 17.39 14 9042 7266 50588802
Pain 19.63 17.39 47 9009 578856 50017212
Colitis ischaemic 19.39 17.39 15 9041 9468 50586600
Confusional state 19.33 17.39 75 8981 185853 50410215
Intra-abdominal haematoma 19.14 17.39 8 9048 1549 50594519
Drug withdrawal syndrome 19.09 17.39 23 9033 25058 50571010
Dysarthria 18.79 17.39 28 9028 37375 50558693
Transaminases increased 18.75 17.39 24 9032 27800 50568268
Hyponatraemia 18.51 17.39 48 9008 96091 50499977
Sedation 18.45 17.39 25 9031 30585 50565483
Renal cyst 18.33 17.39 14 9042 8673 50587395
Urinary retention 18.29 17.39 23 9033 26167 50569901
Nasopharyngitis 18.07 17.39 6 9050 192921 50403147
Hyperthermia 17.57 17.39 13 9043 7683 50588385
Swelling 17.54 17.39 7 9049 200865 50395203
Shock 17.48 17.39 20 9036 20630 50575438

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Coma 151.39 19.41 89 4767 39361 29530310
Hepatitis acute 74.77 19.41 31 4825 6431 29563240
Anticoagulation drug level above therapeutic 47.92 19.41 16 4840 1815 29567856
Wrong patient 45.57 19.41 9 4847 119 29569552
Somnolence 44.17 19.41 65 4791 93890 29475781
Wrong patient received product 40.74 19.41 15 4841 2267 29567404
Acute respiratory distress syndrome 36.09 19.41 30 4826 22905 29546766
Aggression 35.43 19.41 36 4820 35505 29534166
Cor pulmonale acute 34.75 19.41 8 4848 226 29569445
Prothrombin level decreased 30.71 19.41 10 4846 1048 29568623
Faecal vomiting 30.53 19.41 8 4848 390 29569281
Asphyxia 28.56 19.41 15 4841 5300 29564371
Sedation 27.87 19.41 23 4833 17382 29552289
Pneumonia aspiration 27.50 19.41 32 4824 36705 29532966
Toxic skin eruption 27.17 19.41 18 4838 9739 29559932
Dermatitis bullous 27.07 19.41 15 4841 5891 29563780
Overdose 26.25 19.41 47 4809 79772 29489899
Clonus 26.12 19.41 11 4845 2367 29567304
Lung disorder 25.36 19.41 28 4828 30334 29539337
Tachycardia 24.27 19.41 43 4813 72367 29497304
Rhabdomyolysis 24.21 19.41 39 4817 60769 29508902
Abnormal behaviour 24.09 19.41 24 4832 23103 29546568
Dyspnoea 23.86 19.41 12 4844 326720 29242951
Hypothermia 23.23 19.41 16 4840 9223 29560448
Eosinophilia 23.09 19.41 23 4833 22138 29547533
Cardio-respiratory arrest 22.29 19.41 34 4822 50567 29519104
Disturbance in attention 21.88 19.41 22 4834 21402 29548269
Pancreatitis acute 21.25 19.41 23 4833 24362 29545309
Cytotoxic oedema 20.94 19.41 5 4851 166 29569505
Intentional product misuse 20.78 19.41 27 4829 34634 29535037
Electromyogram abnormal 19.97 19.41 4 4852 57 29569614
Rash maculo-papular 19.59 19.41 22 4834 24267 29545404

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Coma 352.43 16.30 213 11782 87402 64399335
Somnolence 117.87 16.30 166 11829 203479 64283258
Suicide attempt 100.05 16.30 92 11903 70915 64415822
Coma blister 96.40 16.30 19 11976 217 64486520
Toxic epidermal necrolysis 74.54 16.30 59 11936 37107 64449630
Overdose 69.41 16.30 114 11881 159452 64327285
Disorientation 68.44 16.30 67 11928 55761 64430976
Hepatitis acute 62.70 16.30 36 11959 13353 64473384
Rhabdomyolysis 57.78 16.30 78 11917 91648 64395089
Neurological decompensation 54.39 16.30 23 11972 4413 64482324
Drug interaction 52.44 16.30 167 11828 361916 64124821
Stupor 50.65 16.30 24 11971 6011 64480726
Erythrodermic psoriasis 48.27 16.30 16 11979 1563 64485174
Seizure 47.06 16.30 99 11896 166793 64319944
Poisoning deliberate 47.05 16.30 30 11965 13428 64473309
Tissue infiltration 44.39 16.30 12 11983 581 64486156
Basal ganglion degeneration 43.82 16.30 11 11984 397 64486340
Dermatitis exfoliative 43.63 16.30 26 11969 10326 64476411
Eosinophilia 43.52 16.30 44 11951 38032 64448705
Aggression 43.21 16.30 48 11947 46184 64440553
Lung disorder 41.89 16.30 54 11941 60646 64426091
Behaviour disorder 41.33 16.30 19 11976 4443 64482294
Uterine enlargement 41.12 16.30 12 11983 769 64485968
Drug abuse 40.22 16.30 81 11914 132293 64354444
Intentional overdose 40.05 16.30 65 11930 89879 64396858
Faecal vomiting 37.91 16.30 12 11983 1013 64485724
Fall 37.49 16.30 165 11830 416661 64070076
Hyperthyroidism 36.74 16.30 29 11966 18150 64468587
Monoplegia 36.15 16.30 16 11979 3427 64483310
Sedation 35.27 16.30 41 11954 41421 64445316
Colitis ischaemic 35.13 16.30 25 11970 13389 64473348
Toxicity to various agents 35.05 16.30 147 11848 363366 64123371
Anticoagulation drug level above therapeutic 34.73 16.30 15 11980 3030 64483707
Neuroleptic malignant syndrome 34.41 16.30 32 11963 24964 64461773
Euphoric mood 34.32 16.30 19 11976 6572 64480165
Anaesthesia 33.83 16.30 9 11986 410 64486327
Prothrombin level decreased 33.53 16.30 12 11983 1474 64485263
Pneumonia aspiration 32.24 16.30 47 11948 59224 64427513
Urinary retention 31.20 16.30 42 11953 49159 64437578
Psychogenic seizure 31.03 16.30 12 11983 1829 64484908
Disturbance in attention 30.64 16.30 38 11957 41036 64445701
Anterograde amnesia 30.05 16.30 9 11986 631 64486106
Wrong patient 29.91 16.30 7 11988 187 64486550
Joint swelling 29.34 16.30 3 11992 215379 64271358
Antithrombin III 29.11 16.30 6 11989 87 64486650
Psychomotor hyperactivity 29.08 16.30 23 11972 14428 64472309
Sudden cardiac death 28.87 16.30 15 11980 4572 64482165
Wrong patient received product 28.66 16.30 14 11981 3748 64482989
Depressed level of consciousness 28.59 16.30 53 11942 81383 64405354
Psychomotor skills impaired 28.37 16.30 14 11981 3831 64482906
Electrolyte imbalance 26.72 16.30 28 11967 25215 64461522
Drug withdrawal syndrome 26.70 16.30 31 11964 31260 64455477
Wrong product administered 26.46 16.30 17 11978 7703 64479034
Respiratory disorder 26.28 16.30 33 11962 36078 64450659
Cardio-respiratory arrest 26.13 16.30 57 11938 98336 64388401
Multiple organ dysfunction syndrome 26.08 16.30 58 11937 101355 64385382
Cor pulmonale acute 26.01 16.30 8 11987 614 64486123
Drug dependence 25.14 16.30 31 11964 33281 64453456
Drug monitoring procedure incorrectly performed 24.85 16.30 7 11988 395 64486342
Shock 24.79 16.30 33 11962 38207 64448530
Derailment 24.36 16.30 5 11990 71 64486666
Miosis 24.33 16.30 20 11975 13246 64473491
Irritability 24.26 16.30 32 11963 36714 64450023
Fatigue 24.20 16.30 66 11929 748664 63738073
Intervertebral disc disorder 23.62 16.30 13 11982 4444 64482293
Social avoidant behaviour 23.35 16.30 13 11982 4544 64482193
Livedo reticularis 23.01 16.30 12 11983 3685 64483052
Cholecystitis 22.99 16.30 23 11972 19613 64467124
Hyponatraemia 22.84 16.30 70 11925 148269 64338468
Hypothermia 22.78 16.30 23 11972 19833 64466904
Serotonin syndrome 22.60 16.30 32 11963 39250 64447487
Loss of consciousness 21.91 16.30 69 11926 148296 64338441
Conversion disorder 21.36 16.30 9 11986 1710 64485027
Somatic delusion 21.12 16.30 7 11988 683 64486054
Electromyogram abnormal 21.04 16.30 5 11990 143 64486594
Rash maculo-papular 20.94 16.30 34 11961 46992 64439745
Inguinal hernia 20.90 16.30 13 11982 5568 64481169
Granulomatous liver disease 20.72 16.30 8 11987 1214 64485523
Pancreatitis acute 20.48 16.30 32 11963 42823 64443914
Mydriasis 19.92 16.30 19 11976 15293 64471444
Tachycardia 19.78 16.30 67 11928 149512 64337225
Dermatitis bullous 19.69 16.30 17 11978 12037 64474700
Dysaesthesia 19.64 16.30 12 11983 4983 64481754
Withdrawal syndrome 19.59 16.30 23 11972 23469 64463268
Hepatocellular injury 19.19 16.30 32 11963 45203 64441534
Lipase increased 18.98 16.30 18 11977 14384 64472353
Asphyxia 18.77 16.30 15 11980 9551 64477186
Hypochromic anaemia 18.60 16.30 9 11986 2359 64484378
Arthralgia 18.31 16.30 34 11961 442226 64044511
Toxic skin eruption 17.97 16.30 20 11975 19264 64467473
Pain 17.69 16.30 49 11946 553462 63933275
Dysarthria 17.60 16.30 36 11959 59370 64427367
Lymphocytosis 17.60 16.30 10 11985 3634 64483103
Bradycardia 17.46 16.30 55 11940 118164 64368573
Abnormal behaviour 17.32 16.30 26 11969 33596 64453141
Sudden death 17.30 16.30 20 11975 20076 64466661
Cutaneous vasculitis 16.80 16.30 12 11983 6461 64480276
Peripheral swelling 16.76 16.30 9 11986 209144 64277593
Confusional state 16.73 16.30 94 11901 261050 64225687
Klebsiella infection 16.37 16.30 16 11979 13265 64473472
Nasopharyngitis 16.36 16.30 8 11987 196065 64290672

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N05BA05 NERVOUS SYSTEM
PSYCHOLEPTICS
ANXIOLYTICS
Benzodiazepine derivatives
FDA CS M0002356 Benzodiazepines
CHEBI has role CHEBI:35474 anti-anxiety agents
CHEBI has role CHEBI:35623 anticonvulsants
CHEBI has role CHEBI:50266 Prodrugs
CHEBI has role CHEBI:50268 GABA modulators
MeSH PA D014151 Anti-Anxiety Agents
MeSH PA D000927 Anticonvulsants
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D018682 GABA Agents
MeSH PA D018757 GABA Modulators
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D011619 Psychotropic Drugs
MeSH PA D014149 Tranquilizing Agents
FDA EPC N0000175694 Benzodiazepine

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Anxiety indication 48694002
Alcohol withdrawal syndrome indication 191480000
Partial Epilepsy Treatment Adjunct indication
Suicidal thoughts contraindication 6471006
Alcohol intoxication contraindication 25702006
Depressive disorder contraindication 35489007
Substance abuse contraindication 66214007
Psychotic disorder contraindication 69322001
Sleep apnea contraindication 73430006 DOID:0050847
Kidney disease contraindication 90708001 DOID:557
Hypoalbuminemia contraindication 119247004
Disease of liver contraindication 235856003 DOID:409
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Severe chronic obstructive pulmonary disease contraindication 313299006
Angle-closure glaucoma contraindication 392291006 DOID:13550
Central nervous system depression contraindication 418072004




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.55 acidic
pKa2 13.86 acidic
pKa3 2.31 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
GABA-A receptor alpha-1/beta-2/gamma-2 Ion channel POSITIVE ALLOSTERIC MODULATOR EC50 7.47 WOMBAT-PK CHEMBL
GABA-A receptor alpha-2/beta-3/gamma-2 Ion channel POSITIVE ALLOSTERIC MODULATOR WOMBAT-PK CHEMBL
GABA-A receptor alpha-3/beta-3/gamma-2 Ion channel POSITIVE ALLOSTERIC MODULATOR WOMBAT-PK CHEMBL
GABA-A receptor alpha-5/beta-3/gamma-2 Ion channel POSITIVE ALLOSTERIC MODULATOR WOMBAT-PK CHEMBL

External reference:

IDSource
D00694 KEGG_DRUG
5991-71-9 SECONDARY_CAS_RN
23887-31-2 SECONDARY_CAS_RN
2353 RXNORM
4018712 VANDF
4019688 VANDF
C0008174 UMLSCUI
CHEBI:59590 CHEBI
CHEMBL1213252 ChEMBL_ID
CHEMBL2106085 ChEMBL_ID
CHEMBL2096631 ChEMBL_ID
DB00628 DRUGBANK_ID
2809 PUBCHEM_CID
7548 IUPHAR_LIGAND_ID
MS63G8NQUI UNII
388 MMSL
4481 MMSL
d00198 MMSL
001456 NDDF
001457 NDDF
001458 NDDF
371349001 SNOMEDCT_US
387453004 SNOMEDCT_US
39815009 SNOMEDCT_US
D003009 MESH_DESCRIPTOR_UI
2224 INN_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Clorazepate Dipotassium HUMAN PRESCRIPTION DRUG LABEL 1 0378-0030 TABLET 3.75 mg ORAL ANDA 19 sections
Clorazepate Dipotassium HUMAN PRESCRIPTION DRUG LABEL 1 0378-0040 TABLET 7.50 mg ORAL ANDA 19 sections
Clorazepate Dipotassium HUMAN PRESCRIPTION DRUG LABEL 1 0378-0070 TABLET 15 mg ORAL ANDA 19 sections
CLORAZEPATE DIPOTASSIUM Human Prescription Drug Label 1 13107-319 TABLET 3.75 mg ORAL ANDA 16 sections
CLORAZEPATE DIPOTASSIUM Human Prescription Drug Label 1 13107-320 TABLET 7.50 mg ORAL ANDA 16 sections
CLORAZEPATE DIPOTASSIUM Human Prescription Drug Label 1 13107-321 TABLET 15 mg ORAL ANDA 16 sections
Clorazepate Dipotassium HUMAN PRESCRIPTION DRUG LABEL 1 21695-433 TABLET 3.75 mg ORAL ANDA 20 sections
Clorazepate Dipotassium HUMAN PRESCRIPTION DRUG LABEL 1 21695-434 TABLET 7.50 mg ORAL ANDA 20 sections
Clorazepate Dipotassium HUMAN PRESCRIPTION DRUG LABEL 1 43063-030 TABLET 15 mg ORAL ANDA 19 sections
Clorazepate Dipotassium HUMAN PRESCRIPTION DRUG LABEL 1 43063-030 TABLET 15 mg ORAL ANDA 19 sections
Clorazepate Dipotassium HUMAN PRESCRIPTION DRUG LABEL 1 43063-893 TABLET 15 mg ORAL ANDA 24 sections
Clorazepate Dipotassium HUMAN PRESCRIPTION DRUG LABEL 1 51672-4042 TABLET 3.75 mg ORAL ANDA 24 sections
Clorazepate Dipotassium HUMAN PRESCRIPTION DRUG LABEL 1 51672-4043 TABLET 7.50 mg ORAL ANDA 24 sections
Clorazepate Dipotassium HUMAN PRESCRIPTION DRUG LABEL 1 51672-4044 TABLET 15 mg ORAL ANDA 24 sections
TranxeneT-Tab HUMAN PRESCRIPTION DRUG LABEL 1 55292-302 TABLET 7.50 mg ORAL NDA 19 sections
TranxeneT-Tab HUMAN PRESCRIPTION DRUG LABEL 1 55292-304 TABLET 7.50 mg ORAL NDA 19 sections
Clorazepate dipotassium HUMAN PRESCRIPTION DRUG LABEL 1 63304-552 TABLET 3.75 mg ORAL ANDA 16 sections
Clorazepate dipotassium HUMAN PRESCRIPTION DRUG LABEL 1 63304-553 TABLET 7.50 mg ORAL ANDA 16 sections
Clorazepate dipotassium HUMAN PRESCRIPTION DRUG LABEL 1 63304-554 TABLET 15 mg ORAL ANDA 16 sections
Clorazepate dipotassium HUMAN PRESCRIPTION DRUG LABEL 1 67046-904 TABLET 7.50 mg ORAL ANDA 16 sections
Clorazepate Dipotassium HUMAN PRESCRIPTION DRUG LABEL 1 67046-906 TABLET 7.50 mg ORAL ANDA 20 sections
Clorazepate dipotassium HUMAN PRESCRIPTION DRUG LABEL 1 67046-907 TABLET 15 mg ORAL ANDA 16 sections